Authors: Aimo Kannt, Sridharan Rajagopal, Mahanandeesha S. Hallur, Indu Swamy, Rajendra Kristam, Saravanakumar Dhakshinamoorthy, Joerg Czech, Gernot Zech, Herman Schreuder and Sven Ruf
Author: ddAdmin
Jubilant Biosys and Yale University announce collaboration
New Haven, CT. & Bengaluru, India—Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.
Jubilant Biosys: A Leading CRO’s Digital Data Transformation
Soy Protein-Based Hydrogel under Microwave-Induced Grafting of Acrylic Acid and 4‑(4-Hydroxyphenyl)butanoic Acid.
Authors: Saloni Mehra, Safiya Nisar, Sonal Chauhan, Virender Singh, and Sunita Rattan
Jubilant Biosys Limited Announces The Merger With Jubilant Chemsys Limited
Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys Limited.
An in vitro model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells
Authors: Hiraganahalli Bhaskar Deepak, Nellikalaya Shreekrishna, Zaheerbasha Sameermahmood, Niranjan Naranapur Anand, Raghotham Hulgi, Juluri Suresh, Sonal Khare, Saravanakumar Dhakshinamoorthy
A CRO that supports drug discovery ideas and passion – Jubilant Biosys
BIO Impact Interview June 2020 with Dr Takeshi Yura
PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits
Authors: Feng Yi, Nirvan Rouzbeh, Kasper B. Hansen, Yuelian Xu, Christopher M. Fanger, Earl Gordon, Kathy Paschetto, Frank S. Menniti,∗, Robert A. Volkmann
Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines
“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of our early-stage companies” Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team.